Clinical Practice, Industry News, Patient Care

Cases of Stomach Paralysis Reported after Taking Semaglutide

July 25, 2023
Weight loss

Drug regulators say they have received reports of stomach paralysis among patients taking GLP-1 agonist drugs.

“The FDA has received reports of gastroparesis with semaglutide and liraglutide, some of which documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said in a statement to CNN.

The reports have been submitted through the agency’s publicly accessible adverse events tracking system, and the agency said there’s not always enough information in those reports to properly evaluate them.

The FDA said it has been unable to determine if the medications were the cause or if the gastroparesis may have been caused by a different issue.

Read more at CNN >>

To read more about the aesthetic history, legal concerns and latest coverage on semaglutide, visit AmSpa’s Medical Aesthetic Semaglutide Resource Center at https://americanmedspa.org/med-spa-semaglutides.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing